Ligelizumab Gets Breakthrough Tx Status for Chronic Spontaneous Urticaria
Ligelizumab is a high-affinity monoclonal anti-immunoglobulin E (IgE) antibody.
Dermatological Disorders
Locally-Delivered Sitaxsentan Designated Orphan Drug for Systemic Sclerosis
TMB-003 is a locally delivered formulation of sitaxsentan, a highly selective endothelin receptor antagonist.
Clinical Challenge: Rash on Soles of Feet
A woman presents for evaluation of a rash affecting both feet that prevents her from walking properly because of pain.
New Drugs Approved in 2020
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Clinical Challenge: Asymptomatic Growth on Cheek
A woman requests the removal of an asymptomatic growth on her cheek that has been present for 1 year.
Clinical Challenge: Growth Under Eyes
A 51-year-old woman requested removal of growths under both eyes. Can you make the correct diagnosis?
Klisyri Ointment Approved for Actinic Keratosis
The approval was based on data from 2 multicenter, randomized, double-blind, phase 3 trials that evaluated the efficacy and safety of Klisyri ointment in adults with AK on the face or scalp.
Upadacitinib Bests Dupilumab in Atopic Dermatitis Trial
The randomized, double-blind, double-dummy, active-controlled Heads Up study included 692 patients aged 18 to 75 years with moderate to severe atopic dermatitis who are candidates for systemic therapy.
New Drug Product: Zilxi
This slideshow shows drug information for Zilxi. Click here for the complete Zilxi monograph.
Clinical Challenge: Nonpruritic Rash Affecting Both Legs
A 38-year-old woman presents with a rash affecting her legs. Can you make the correct diagnosis?
